CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality

The Lancet Oncology

Fecha de publicación: 16 December 2019

DOI: https://doi.org/10.1016/S1470-2045(19)30808-3

Autores: Giuseppe Curigliano, Sibylle Loibl

Background: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) have been widely incorporated into the care of women with metastatic hormone receptor-positive, HER2-negative breast cancer.